What is your advice with regard to monitoring patients undergoing treatment with glofitamab or other bispecifics to promptly identify and manage adverse events such as CRS and ICANs?
M-BE-00002927
Polivy SmPC - 24/05/2022 : https://www.e-compendium.be/fr/notices/scientifique/7929/18885